Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01994174 · ClinicalTrials.gov registry record
Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
A clinical trial, sponsored by University of Nebraska.
- Terminated
- Registry status
- 13
- Enrollment target
NCT01994174 is a clinical trial that was terminated before completion, run by University of Nebraska. The registered enrollment target is 13 participants.
The verdict
NCT01994174 was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab, ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular disease. The underlying hypothesis is that anti-VEGF drugs increase intraocular pressure (IOP) by increasing aqueous inflow, decreasing uveoscleral outflow or both. The specific aim is to evaluate the changes produced in AHD after 1 baseline and a subsequent 1 monthly injection of anti VEGF agents.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-12-20 |
| Est. Completion | 2023-01-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01994174
The ClinicalTrials.gov registry entry for NCT01994174 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01994174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01994174 about?
NCT01994174 is a clinical study titled "Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics". The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab, ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular disease. The underlying hypothesis is that anti-VEGF drugs increase intraocular pressure (IOP) by increasing aqueo...
What is the current status of trial NCT01994174?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2013-12-20. Estimated completion is 2023-01-12.
Who is sponsoring clinical trial NCT01994174?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.